218 related articles for article (PubMed ID: 26912182)
21. Design and evaluation of a pharmacogenomics information resource for pharmacists.
Romagnoli KM; Boyce RD; Empey PE; Ning Y; Adams S; Hochheiser H
J Am Med Inform Assoc; 2017 Jul; 24(4):822-831. PubMed ID: 28339805
[TBL] [Abstract][Full Text] [Related]
22. Learning from product labels and label changes: how to build pharmacogenomics into drug-development programs.
Surh LC; Pacanowski MA; Haga SB; Hobbs S; Lesko LJ; Gottlieb S; Papaluca-Amati M; Patterson SD; Hughes AR; Kim MJ; Close SL; Mosteller M; Zineh I; Dechairo B; Cohen NA
Pharmacogenomics; 2010 Dec; 11(12):1637-47. PubMed ID: 21142906
[TBL] [Abstract][Full Text] [Related]
23. Ontogeny and the Application of Pharmacogenomics to Pediatric Drug Development.
Green D
J Clin Pharmacol; 2019 Sep; 59 Suppl 1():S82-S86. PubMed ID: 31502695
[TBL] [Abstract][Full Text] [Related]
24. Pharmacogenomics: history, barriers, and regulatory solutions.
Blankstein S
Food Drug Law J; 2014; 69(2):273-314, ii. PubMed ID: 25163212
[TBL] [Abstract][Full Text] [Related]
25. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
26. Health regulatory communications of well-established safety-related pharmacogenomics associations in six developed countries: an evaluation of alignment.
Tan-Koi WC; Lim ES; Teo YY
Pharmacogenomics J; 2017 Mar; 17(2):121-127. PubMed ID: 26902540
[TBL] [Abstract][Full Text] [Related]
27. Quantitation of Targetable Somatic Mutations Among Patients Evaluated by a Personalized Medicine Clinical Service: Considerations for Off-Label Drug Use.
Vela CM; Knepper TC; Gillis NK; Walko CM; McLeod HL; Hicks JK
Pharmacotherapy; 2017 Sep; 37(9):1043-1051. PubMed ID: 28235141
[TBL] [Abstract][Full Text] [Related]
28. Availability of pharmacogenetic and pharmacogenomic information in anticancer drug monographs in France: personalized cancer therapy.
Albertini L; Siest G; Jeannesson E; Visvikis-Siest S
Pharmacogenomics; 2011 May; 12(5):681-91. PubMed ID: 21619430
[TBL] [Abstract][Full Text] [Related]
29. An Evidence-Based Framework for Evaluating Pharmacogenomics Knowledge for Personalized Medicine.
Whirl-Carrillo M; Huddart R; Gong L; Sangkuhl K; Thorn CF; Whaley R; Klein TE
Clin Pharmacol Ther; 2021 Sep; 110(3):563-572. PubMed ID: 34216021
[TBL] [Abstract][Full Text] [Related]
30. Implementing the U.S. FDA guidance on pharmacogenomic data submissions.
Goodsaid F; Frueh FW
Environ Mol Mutagen; 2007 Jun; 48(5):354-8. PubMed ID: 17567848
[TBL] [Abstract][Full Text] [Related]
31. Implementing a personalized medicine program in a community health system.
Dressler LG; Bell GC; Ruch KD; Retamal JD; Krug PB; Paulus RA
Pharmacogenomics; 2018 Nov; 19(17):1345-1356. PubMed ID: 30345883
[TBL] [Abstract][Full Text] [Related]
32. Analyzing the clinical actionability of germline pharmacogenomic findings in oncology.
Wellmann R; Borden BA; Danahey K; Nanda R; Polite BN; Stadler WM; Ratain MJ; O'Donnell PH
Cancer; 2018 Jul; 124(14):3052-3065. PubMed ID: 29742281
[TBL] [Abstract][Full Text] [Related]
33. Clinical Trial Designs to Support Clinical Utility of Pharmacogenomic Testing.
Drozda K; Pacanowski MA
Pharmacotherapy; 2017 Sep; 37(9):1000-1004. PubMed ID: 28605049
[TBL] [Abstract][Full Text] [Related]
34. Pharmacogenomic biomarkers: validation needed for both the molecular genetic mechanism and clinical effect.
Sadee W
Pharmacogenomics; 2011 May; 12(5):675-80. PubMed ID: 21619429
[TBL] [Abstract][Full Text] [Related]
35. Pharmacogenomic biomarkers: Interpretation of information included in United States and Japanese drug labels.
Shimazawa R; Ikeda M
J Clin Pharm Ther; 2018 Aug; 43(4):500-506. PubMed ID: 29722046
[TBL] [Abstract][Full Text] [Related]
36. Patient-provider communications about pharmacogenomic results increase patient recall of medication changes.
Borden BA; Lee SM; Danahey K; Galecki P; Patrick-Miller L; Siegler M; Sorrentino MJ; Sacro Y; Davis AM; Rubin DT; Lipstreuer K; Polonsky TS; Nanda R; Harper WR; Koyner JL; Burnet DL; Stadler WM; Kavitt RT; Meltzer DO; Ratain MJ; O'Donnell PH
Pharmacogenomics J; 2019 Dec; 19(6):528-537. PubMed ID: 30713337
[TBL] [Abstract][Full Text] [Related]
37. Pharmacogenomics Implementation: Considerations for Selecting a Reference Laboratory.
Vo TT; Bell GC; Owusu Obeng A; Hicks JK; Dunnenberger HM
Pharmacotherapy; 2017 Sep; 37(9):1014-1022. PubMed ID: 28699700
[TBL] [Abstract][Full Text] [Related]
38. Comparison of pharmacogenomic information for drug approvals provided by the national regulatory agencies in Korea, Europe, Japan, and the United States.
Lee M; Han JM; Lee J; Oh JY; Kim JS; Gwak HS; Choi KH
Front Pharmacol; 2023; 14():1205624. PubMed ID: 37361213
[TBL] [Abstract][Full Text] [Related]
39. The Role of Pharmacogenomics in Bipolar Disorder: Moving Towards Precision Medicine.
Pisanu C; Heilbronner U; Squassina A
Mol Diagn Ther; 2018 Aug; 22(4):409-420. PubMed ID: 29790107
[TBL] [Abstract][Full Text] [Related]
40. Characterizing Pharmacogenomic-Guided Medication Use With a Clinical Data Repository.
Mathias PC; Hendrix N; Wang WJ; Keyloun K; Khelifi M; Tarczy-Hornoch P; Devine B
Clin Pharmacol Ther; 2017 Aug; 102(2):340-348. PubMed ID: 28073152
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
